Target+-+3-oxoacyl-(acyl-carrier+protein)+reductase+(T.+Cruzi)


 * Target (protein/gene name):** 3-oxoacyl-(acyl-carrier protein) reductase, putative

[|3548181]
 * NCBI Gene #:**

[|XP_816315.1]
 * Protein ID (NP or XP #):**

Risk Group 2 (RG2) - Parasitic Agents
 * Organism:** //Trypanosoma cruzi//
 * Etiologic Risk Group (see link below):**

Chagas disease is a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi. T. cruzi is commonly transmitted to humans and other mammals by an insect vector, the blood-sucking "kissing bugs" of the subfamily Triatominae (family Reduviidae) most commonly species belonging to the Triatoma, Rhodnius, and Panstrongylus genera. The disease may also be spread through blood transfusion and organ transplantation, ingestion of food contaminated with parasites, and from a mother to her fetus. The symptoms of Chagas disease vary over the course of an infection. In the early, acute stage, symptoms are mild and usually produce no more than local swelling at the site of infection. The initial acute phase is responsive to antiparasitic treatments, with 60–90% cure rates. After 4–8 weeks, individuals with active infections enter the chronic phase of Chagas disease that is asymptomatic for 60–80% of chronically infected individuals through their lifetime. The antiparasitic treatments also appear to delay or prevent the development of disease symptoms during the chronic phase of the disease, but 20–40% of chronically infected individuals will still eventually develop life-threatening heart and digestive system disorders. The currently available antiparasitic treatments for Chagas disease are benznidazole and nifurtimox, which can cause temporary side effects in many patients including skin disorders, brain toxicity, and digestive system irritation. Chagas disease is contracted primarily in the Americas, particularly in poor, rural areas of Mexico, Central America, and South America; very rarely, the disease has originated in the Southern United States. The insects that spread the disease are known by various local names, including vinchuca in Argentina, Bolivia, Chile and Paraguay, barbeiro (the barber) in Brazil, pito in Colombia, chinche in Central America, chipo in Venezuela, chupança, chinchorro, and "the kissing bug". It is estimated that as many as 8 to 11 million people in Mexico, Central America, and South America have Chagas disease, most of whom do not know they are infected. Large-scale population movements from rural to urban areas of Latin America and to other regions of the world have increased the geographic distribution of Chagas disease, and cases have been noted in many countries, particularly in Europe. Control strategies have mostly focused on eliminating the triatomine insect vector and preventing transmission from other sources. --Wikipedia
 * Background/Disease Information:**


 * Essentiality of this protein:**

[]
 * Complex of enzymes:**
 * EC#: 6.3.1.2**
 * Link to BRENDA EC# page:**
 * Enzyme Assay information (spectrophotometric, coupled assay ?, reagents):**
 * -- link to Sigma (or other company) page for assay or assay reagents (substrates)**
 * -- link to paper that contains assay information**


 * Structure Available (PDB or Homology model)**
 * -- PDB # or closest PDB entry if using homology model:** 1EDO
 * -- Query Coverage (if not direct match):** 95%
 * -- Max Ident (if not direct match):** 30%


 * Substrate Info:**
 * SKU:** A1625-5MG
 * Price: **124.50
 * Druggable Target (see Databases for this):**
 * Current Inhibitors:**
 * Expression Information (has it been expressed in bacterial cells):**
 * Purification Method:**
 * Image of protein (PyMol or etc):**
 * Amino Acid Sequence:**
 * length of your protein in Amino Acids**
 * Molecular Weight of your protein in kiloDaltons using the [|Expasy ProtParam] website**
 * Molar Extinction coefficient of your protein at 280 nm wavelength:**
 * CDS Gene Sequence:**
 * GC% Content for gene:**
 * CDS Gene Sequence (codon optimized) - after having done Primer Design:**
 * GC% Content for gene (codon optimized):**


 * Primer design results for pNIC-Bsa4 cloning (list seqeunces of all of your ~40 nt long primers):**


 * Primer design results for 'tail' primers (this is just 2 sequences):**